Cargando…
PPARγ agonists inhibit growth and expansion of CD133+ brain tumour stem cells
Brain tumour stem cells (BTSCs) are a small population of cells that has self-renewal, transplantation, multidrug resistance and recurrence properties, thus remain novel therapeutic target for brain tumour. Recent studies have shown that peroxisome proliferator-activated receptor gamma (PPARγ) agoni...
Autores principales: | Chearwae, W, Bright, J J |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2008
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2607234/ https://www.ncbi.nlm.nih.gov/pubmed/19018263 http://dx.doi.org/10.1038/sj.bjc.6604786 |
Ejemplares similares
-
Expansion of CD133(+) colon cancer cultures retaining stem cell properties to enable cancer stem cell target discovery
por: Fang, D D, et al.
Publicado: (2010) -
PPARγ Agonists Promote Oligodendrocyte Differentiation of Neural Stem Cells by Modulating Stemness and Differentiation Genes
por: Kanakasabai, Saravanan, et al.
Publicado: (2012) -
PPARγ agonists regulate the expression of stemness and differentiation genes in brain tumour stem cells
por: Pestereva, E, et al.
Publicado: (2012) -
Prognostic impact of the expression of putative cancer stem cell markers CD133, CD166, CD44s, EpCAM, and ALDH1 in colorectal cancer
por: Lugli, A, et al.
Publicado: (2010) -
CD133 expression is an independent prognostic marker for low survival in colorectal cancer
por: Horst, D, et al.
Publicado: (2008)